AtriCure (NASDAQ:ATRC) Sets New 52-Week High – Still a Buy?

Shares of AtriCure, Inc. (NASDAQ:ATRC) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $43.18 and last traded at $42.9250, with a volume of 363599 shares. The stock had previously closed at $41.64.

Wall Street Analyst Weigh In

Several analysts have weighed in on ATRC shares. Canaccord Genuity Group upped their target price on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. UBS Group cut their price target on AtriCure from $55.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Zacks Research upgraded shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 24th. Weiss Ratings upgraded shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a research report on Tuesday, July 28th. Finally, Raymond James Financial set a $52.00 price objective on shares of AtriCure in a research note on Tuesday, July 21st. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, AtriCure has an average rating of “Moderate Buy” and a consensus price target of $48.50.

AtriCure Trading Up 1.3%

The business has a 50 day moving average of $33.24 and a 200-day moving average of $31.40. The stock has a market cap of $2.25 billion, a PE ratio of 208.97 and a beta of 1.20. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The company had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. During the same quarter last year, the business posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, analysts anticipate that AtriCure, Inc. will post 0.2 EPS for the current year.

Insider Activity

In other AtriCure news, insider Justin J. Noznesky sold 6,182 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total transaction of $239,861.60. Following the sale, the insider directly owned 100,219 shares of the company’s stock, valued at $3,888,497.20. This trade represents a 5.81% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Vinayak Doraiswamy sold 6,000 shares of AtriCure stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $38.88, for a total transaction of $233,280.00. Following the sale, the insider owned 86,511 shares of the company’s stock, valued at approximately $3,363,547.68. This trade represents a 6.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 47,246 shares of company stock worth $1,777,845 in the last quarter. Corporate insiders own 4.00% of the company’s stock.

Institutional Trading of AtriCure

Hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC raised its holdings in AtriCure by 1.0% in the 1st quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock valued at $2,700,000 after acquiring an additional 837 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of AtriCure by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock worth $908,000 after purchasing an additional 1,230 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of AtriCure by 1.0% in the first quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock valued at $27,830,000 after purchasing an additional 8,956 shares during the period. Jane Street Group LLC grew its position in shares of AtriCure by 658.3% in the first quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock valued at $3,254,000 after purchasing an additional 87,553 shares during the period. Finally, Strs Ohio acquired a new position in AtriCure in the first quarter valued at $158,000. Institutional investors and hedge funds own 99.11% of the company’s stock.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.